WO2004046163A1 - エルゴステロールの分離方法 - Google Patents
エルゴステロールの分離方法 Download PDFInfo
- Publication number
- WO2004046163A1 WO2004046163A1 PCT/JP2003/014170 JP0314170W WO2004046163A1 WO 2004046163 A1 WO2004046163 A1 WO 2004046163A1 JP 0314170 W JP0314170 W JP 0314170W WO 2004046163 A1 WO2004046163 A1 WO 2004046163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergosterol
- water
- organic solvent
- insoluble organic
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention relates to a method for separating ergosterol.
- Ergosterol is a useful sterol contained in microorganisms such as fungi, which is a precursor of vitamin D2. It is known that when this ergosterol is crystallized in a water-insoluble organic solvent, a granular aggregate having good solid-liquid separation properties can be obtained (Japanese Patent Laid-Open No. 2002-80492). However, in this case, the actual yield is significantly lower than the crystal yield expected from the solubility of ergosterol in the organic solvent, and the unrecovered portion is more flocculent than the filtrate after solid-liquid separation. There was a problem that it became fine crystals and gradually precipitated.
- the present invention provides a solution to the above-mentioned problem of the deterioration of the yield, and by obtaining enolegosterol crystals in a high yield, it is preferable that the solidification of ergosterol having good solid-liquid separation property is achieved.
- An object of the present invention is to provide an industrially advantageous method for separating ergosterol by allowing the aggregate to be obtained in a high yield.
- the method for separating ergosterol according to the present invention is characterized by supplying water to a water-insoluble organic solvent solution. According to the present invention, generation of ergosterol crystals is promoted, and a high yield can be achieved. In addition, the amount of water to supply By controlling the concentration, the formation of ergosterol aggregates having good solid-liquid separation properties is promoted, and a high yield can be achieved. In addition, the ergosterol aggregate obtained when the amount of water is controlled contains an amorphous component in the crystal and has a crystallization rate of 5%.
- An aggregate of about 0 to 90% can be obtained.
- the present invention provides a method for separating ergosterol, wherein when ergosterol is separated from a water-insoluble organic solvent solution containing ergosterol, water is supplied to the solution to precipitate ergosterol. About.
- the present invention also relates to the above method, wherein the amount of water to be supplied is within a range not separating into a water-insoluble organic solvent and two liquid phases.
- the present invention provides a method of extracting ergosterol from a microorganism containing ergosterol with a water-insoluble organic solvent, the method comprising the steps of: The above method, wherein the solution is a solution that has been exchanged for a water-insoluble organic solvent after extraction with the above;
- the water-insoluble organic solvent is hexane, heptane, octane or a mixture thereof;
- the method of supplying water is a method of continuously or intermittently humidifying a gas phase portion of an apparatus for depositing ergosterol
- the present invention relates to the above method, wherein ergosterol precipitated and separated is an aggregate having a crystallization ratio of 50% to 90%.
- the present invention also relates to an ergosterol aggregate having a crystallization ratio of 50% to 90%.
- the method for separating ergosterol of the present invention is characterized in that ergosterol is precipitated by supplying water to a water-insoluble organic solvent solution containing ergosterol.
- Ergosterol is a useful sterol contained in microorganisms such as fungi, which is a precursor of vitamin D2.
- Representative fungi include shiitake, Mushrooms such as maitake; yeast; rhizobia and the like found in the roots of legumes.
- Other microorganisms include unicellular algae such as chlorella.
- the water-insoluble organic solvent as referred to in the present invention refers to a substance whose general property is shown to be insoluble or hardly soluble in water according to, for example, chemical substance safety data.
- Aliphatic hydrocarbons such as benzene, heptane and octane; aromatic hydrocarbons such as benzene, toluene and xylene; and halogenated hydrocarbons such as methylene chloride, chloroform and carbon tetrachloride. These can be used alone or in combination of two or more. Among these, an aliphatic hydrocarbon having low solubility of ergosterol is preferred from the viewpoint that it is necessary to perform an operation of precipitating ergosterol. Among them, hexane, heptane, octane, and mixtures thereof are more preferable.
- water-insoluble organic solvent solution containing ergosterol examples include, for example, a water-insoluble organic solvent solution in which only ergosterol is dissolved; a water-insoluble organic solvent solution from microorganisms such as fungi containing ergosterol.
- solvents used for the extraction include, for example, water-soluble organic solvents such as acetone, ethanol and 2-propanol; and mixtures of these water-soluble organic solvents and the above-mentioned water-insoluble organic solvents.
- the obtained extract When ergosterol is extracted from microorganisms such as fungi containing ergosterol with a water-insoluble organic solvent, the obtained extract may be used as it is in the next precipitation step, or After extraction with a more soluble water-insoluble organic solvent (aromatic hydrocarbon, halogenated hydrocarbon), it is converted into a less water-soluble organic solvent (aliphatic hydrocarbon) with lower ergosterol solubility. The exchanged solution may be used in the next precipitation step.
- a more soluble water-insoluble organic solvent aromatic hydrocarbon, halogenated hydrocarbon
- a cooling crystallization method in which the solubility is lowered by lowering the solution temperature to lower the solubility to precipitate the target substance, as is generally known, or an organic method.
- Evaporation crystallization in which the target substance is precipitated by evaporating and concentrating the solvent, can be applied. It is preferable to use the cooling crystallization method rather than the evaporation crystallization method in which water evaporates and is lost.
- the apparatus used for the precipitation of ergosterol is not particularly limited, but, for example, a batch type crystallizer using a jacketed stirring tank, or a liquid continuously supplied from one or more stirring tanks with a jacket. Examples include a continuous crystallizer for supplying and extracting, and a columnar continuous crystallizer.
- water is supplied when ergosterol is precipitated, and the amount of supplied water is preferably in a range that does not separate into a water-insoluble organic solvent and two liquid phases.
- the amount of water that does not separate into the water-insoluble organic solvent and the two liquid phases is the amount of a trace amount of water that can be dissolved in the water-insoluble organic solvent.
- the amount of the water is related to the solubility of the water in the water-insoluble organic solvent and varies somewhat depending on the type of the water-insoluble organic solvent.For example, hexane is used as the water-insoluble organic solvent. In this case, the amount of water is preferably about 1 to 100 ppm based on hexane.
- a method of supplying water by humidifying the gas phase portion (portion where gas exists) in the apparatus for precipitating ergosterol is used to maintain the liquid phase in a uniform state.
- the method of humidifying the gas phase is not particularly limited as long as water can be supplied to such an extent that it does not separate into two liquid phases. For example, a method of directly feeding steam; a flow of nitrogen gas or the like passed through water A method of supplying atomized water generated by using an ultrasonic humidifier; a method of flowing a gas that has passed through the generated atomized water.
- water is supplied by continuously or intermittently humidifying the gas phase part of the apparatus for precipitating ergosterol.
- the crystallization temperature is preferably from 130 to 80 ° C, more preferably from 120 to 60 ° C.
- the crystallization time is preferably 0.5 to 24 hours, more preferably 1 to 6 hours.
- the cooling rate is preferably 0.05 to 3 ° C / min, more preferably 0.1 to 1 ° C.
- the recovery of ergosterol is preferably at least 60%, more preferably at least 70%, further preferably at least 80%, particularly preferably at least 90%.
- ergosterol precipitated and separated by controlling the amount of water to be supplied is a granular aggregate having good solid-liquid separation properties. It is not just a hydrate crystal, but an agglomerate containing hydrate crystals and an amorphous component in the crystal. Since the amorphous component does not contain water of crystallization, aggregates can be efficiently precipitated with a smaller amount of water than is necessary to obtain the entire amount as hydrate crystals, and the yield can be improved. . For this reason, it is preferable that the amorphous component is large, but if it is too large, it cannot be obtained as an aggregate. Therefore, the crystallization ratio of the ergosterol aggregate is preferably 50% or more and 90% or less, more preferably 60% or more and 80% or less.
- the crystallization ratio can be measured by X-ray diffraction or the like, but can also be determined by measuring hydrated water by thermogravimetric analysis.
- the value determined by measuring by thermogravimetric analysis is adopted as the crystallization ratio.
- thermogravimetric analysis is performed on the naturally dried agglomerates so that water of crystallization is not lost, and the amount of crystal components in the agglomerates, that is, the crystallization ratio, can be obtained by measuring the water content. .
- the crystallization ratio is determined as follows.
- the particle size of the obtained granular aggregate is preferably at least 50 / xm, more preferably at least 100 ⁇ m.
- the obtained crystals were granular aggregates with a particle size of 100 to 200 ⁇ m, had good solid-liquid separation properties, and had a good recovery (based on the amount charged and the solution concentration measured) of 78%.
- a thermogravimetric analyzer (TG / DTA220, manufactured by Seiko Denshi Kogyo)
- the temperature was increased from 30 ° C to 180 ° C at 10 ° C / min, the weight loss was measured, and the crystallization ratio was determined.
- the crystallization ratio of this aggregate was 66%.
- a hexane solution of ergosterol adjusted to a concentration of 4 g / L was continuously supplied to a tower-type continuous crystallizer having an inner diameter of 3 Omm and a height of 45 Omm.
- the operation of the crystallizer was performed at a temperature at the outlet at the top of the tower of 10 ° C, a stirring rotation speed of 100 rpm, and a liquid supply speed of 5 m1 / min (The feed liquid was kept at about 50 ° C.)
- the average residence time was 60 minutes.
- the humidified nitrogen gas was passed through the trap tube filled with water from the nozzle through the gas phase at the upper end of the device.
- a hexane solution containing enoregosterol at a concentration of 4 g / L (50 Om1) was filtered into a batch type crystallizer using a 500 ml separable flask, and charged from 45 ° C to 10 ° C with stirring. It was cooled at 0.2 ° C. During cooling, 0.5 ml of water was added. The added water could not be dissolved in hexane and remained as droplets until the end of cooling. After cooling, solid-liquid separation was performed, and the crystals were dried under reduced pressure and taken out. The recovery (measured on the basis of the charged amount and the solution concentration) was as good as 87%, but the crystals were needle-shaped. In addition, thermogravimetric analysis was carried out in the same manner as described above, and the crystallization ratio of this crystal was 95%.
- ergosterol crystals can be obtained in high yield.
- by controlling the amount of water supplied it is possible to obtain a high-yield granular ergosterol aggregate having good solid-liquid separation properties.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004553147A JP4532281B2 (ja) | 2002-11-08 | 2003-11-07 | エルゴステロールの分離方法 |
EP03811497A EP1559720A1 (en) | 2002-11-08 | 2003-11-07 | Method of separating ergosterol |
US10/532,682 US7884221B2 (en) | 2002-11-08 | 2003-11-07 | Method of separating ergosterol |
AU2003277589A AU2003277589A1 (en) | 2002-11-08 | 2003-11-07 | Method of separating ergosterol |
US12/929,034 US20110098493A1 (en) | 2002-11-08 | 2010-12-23 | Method of separating ergosterol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-325381 | 2002-11-08 | ||
JP2002325381 | 2002-11-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/929,034 Division US20110098493A1 (en) | 2002-11-08 | 2010-12-23 | Method of separating ergosterol |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004046163A1 true WO2004046163A1 (ja) | 2004-06-03 |
Family
ID=32321618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/014170 WO2004046163A1 (ja) | 2002-11-08 | 2003-11-07 | エルゴステロールの分離方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7884221B2 (ja) |
EP (1) | EP1559720A1 (ja) |
JP (1) | JP4532281B2 (ja) |
KR (1) | KR20050084930A (ja) |
CN (1) | CN1324042C (ja) |
AU (1) | AU2003277589A1 (ja) |
TW (1) | TW200418872A (ja) |
WO (1) | WO2004046163A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100559263B1 (ko) | 2004-08-31 | 2006-03-15 | 한국생명공학연구원 | 표고버섯으로부터 에르고스테롤 에폭사이드 및생리학적으로 허용되는 이의 염을 제조하는 방법 |
JP2006305450A (ja) * | 2005-04-27 | 2006-11-09 | Kaneka Corp | ステロール類の晶析方法およびそのシステム |
US7994187B2 (en) | 2006-04-03 | 2011-08-09 | Tibotec Pharmaceuticals Ltd. | HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones |
US8349839B2 (en) | 2009-04-09 | 2013-01-08 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112209984B (zh) * | 2020-11-18 | 2022-12-02 | 河北兰升生物科技有限公司 | 甲磺酰麦角甾醇的改进制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50142787A (ja) * | 1974-04-25 | 1975-11-17 | ||
GB2107715A (en) * | 1981-10-19 | 1983-05-05 | Glaxo Group Ltd | Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it |
EP0626388A2 (en) * | 1993-05-28 | 1994-11-30 | Nippon Kayaku Kabushiki Kaisha | 14Alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same |
JP2002080492A (ja) * | 2000-09-01 | 2002-03-19 | Kanegafuchi Chem Ind Co Ltd | エルゴステロールの回収方法 |
JP2002080493A (ja) * | 2000-09-06 | 2002-03-19 | Kanegafuchi Chem Ind Co Ltd | ステロール類の精製方法 |
JP2002105097A (ja) * | 2000-09-29 | 2002-04-10 | Kanegafuchi Chem Ind Co Ltd | ステロール類の回収方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1842929A (en) * | 1928-04-09 | 1932-01-26 | Mead Johnson & Co | Process of preparing ergosterol |
US1775548A (en) * | 1928-04-09 | 1930-09-09 | Mead Johnson & Co | Process of purifying ergosterol |
US2167272A (en) * | 1938-07-09 | 1939-07-25 | Gen Mills Inc | Process of producing crystalline ergosterol |
US2536753A (en) * | 1948-02-09 | 1951-01-02 | Veenendaalsche Sajet En Vijfsc | Recovery and purification of sterols |
US2730536A (en) * | 1952-05-01 | 1956-01-10 | Pfizer & Co C | Recovery of ergosterol |
BE794467A (fr) * | 1972-01-28 | 1973-07-24 | Takeda Chemical Industries Ltd | Procede de production d'ergosterol et de ses esters |
JPS5933354B2 (ja) * | 1976-09-14 | 1984-08-15 | 鐘淵化学工業株式会社 | 補酵素qの製造法 |
KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
CA2118979C (en) * | 1993-03-18 | 2003-02-25 | Spencer M. Nimberger | Sampling pump |
JP2663105B2 (ja) * | 1993-05-28 | 1997-10-15 | 雪印乳業株式会社 | 14α−ヒドロキシ−4−アンドロステン−3,6,17−トリオン水和物結晶及びその製造法 |
US5648245A (en) * | 1995-05-09 | 1997-07-15 | Carnegie Institution Of Washington | Method for constructing an oligonucleotide concatamer library by rolling circle replication |
US6124120A (en) * | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
WO2000015779A2 (en) * | 1998-09-15 | 2000-03-23 | Yale University | Molecular cloning using rolling circle amplification |
-
2003
- 2003-11-07 KR KR1020057007883A patent/KR20050084930A/ko not_active Application Discontinuation
- 2003-11-07 TW TW092131259A patent/TW200418872A/zh unknown
- 2003-11-07 JP JP2004553147A patent/JP4532281B2/ja not_active Expired - Fee Related
- 2003-11-07 AU AU2003277589A patent/AU2003277589A1/en not_active Abandoned
- 2003-11-07 EP EP03811497A patent/EP1559720A1/en not_active Withdrawn
- 2003-11-07 WO PCT/JP2003/014170 patent/WO2004046163A1/ja active Application Filing
- 2003-11-07 US US10/532,682 patent/US7884221B2/en active Active
- 2003-11-07 CN CNB2003801021537A patent/CN1324042C/zh not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/929,034 patent/US20110098493A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50142787A (ja) * | 1974-04-25 | 1975-11-17 | ||
GB2107715A (en) * | 1981-10-19 | 1983-05-05 | Glaxo Group Ltd | Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it |
EP0626388A2 (en) * | 1993-05-28 | 1994-11-30 | Nippon Kayaku Kabushiki Kaisha | 14Alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same |
JP2002080492A (ja) * | 2000-09-01 | 2002-03-19 | Kanegafuchi Chem Ind Co Ltd | エルゴステロールの回収方法 |
JP2002080493A (ja) * | 2000-09-06 | 2002-03-19 | Kanegafuchi Chem Ind Co Ltd | ステロール類の精製方法 |
JP2002105097A (ja) * | 2000-09-29 | 2002-04-10 | Kanegafuchi Chem Ind Co Ltd | ステロール類の回収方法 |
Non-Patent Citations (2)
Title |
---|
DATABASE CAPLUS HULL, S ET AL: "The crystal structure of ergosterol monohydrate", XP002977461 * |
STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, vol. B32, no. 8, 1976, pages 2370 - 2373 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100559263B1 (ko) | 2004-08-31 | 2006-03-15 | 한국생명공학연구원 | 표고버섯으로부터 에르고스테롤 에폭사이드 및생리학적으로 허용되는 이의 염을 제조하는 방법 |
JP2006305450A (ja) * | 2005-04-27 | 2006-11-09 | Kaneka Corp | ステロール類の晶析方法およびそのシステム |
US7994187B2 (en) | 2006-04-03 | 2011-08-09 | Tibotec Pharmaceuticals Ltd. | HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones |
US8349839B2 (en) | 2009-04-09 | 2013-01-08 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
Also Published As
Publication number | Publication date |
---|---|
US20060167290A1 (en) | 2006-07-27 |
JPWO2004046163A1 (ja) | 2006-03-16 |
CN1324042C (zh) | 2007-07-04 |
KR20050084930A (ko) | 2005-08-29 |
JP4532281B2 (ja) | 2010-08-25 |
EP1559720A1 (en) | 2005-08-03 |
US7884221B2 (en) | 2011-02-08 |
CN1708508A (zh) | 2005-12-14 |
AU2003277589A1 (en) | 2004-06-15 |
TW200418872A (en) | 2004-10-01 |
US20110098493A1 (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6419071B2 (ja) | ナノサイズ鉄リン酸塩粒子の製造方法 | |
JP2002521181A (ja) | ガス流から硫化水素を除去するプロセスのための改良再生方法 | |
JP2001510465A (ja) | 2,4,6,8,10,12−ヘキサニトロ−2,4,6,8,10,12−ヘキサアザテトラシクロ[5.5.0.0▲上5.9▼0▲上3.11▼]−ドデカンを結晶化させる塩析法 | |
US8226923B2 (en) | Method for production of ammonium paratungstate tetrahydrate and highly pure ammonium paratungstate tetrahydrate | |
US20110098493A1 (en) | Method of separating ergosterol | |
CN112592491A (zh) | 一种基于离子液体微乳液的金属有机框架的制备方法 | |
CN101415667B (zh) | 芳香族羧酸的干燥方法和干燥芳香族羧酸的制造方法 | |
JPH11310414A (ja) | 高純度炭酸リチウムの製造法 | |
JP4731980B2 (ja) | ステロール類の晶析方法およびそのシステム | |
JP2012101998A (ja) | 高純度シリコン微粉末の製造装置 | |
EP2269982B1 (en) | Method for crystallization of 2-amino-2-[2-[4-(3- benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride | |
CN103073601B (zh) | 一种2-酮基-l-古龙酸溶液加晶种的可控浓缩结晶方法 | |
KR101137682B1 (ko) | 용해도 조절에 의한 거대 결정입자의 제조방법 | |
CN104308174B (zh) | 分散和/或纯化纳米金片的方法 | |
JPH11310413A (ja) | 高純度炭酸リチウムの製造方法 | |
CN114901590A (zh) | 用于生产双(氟磺酰)亚胺的集成方法 | |
JP4549972B2 (ja) | パラヒドロキシ安息香酸無水和物の結晶およびその製造方法 | |
CN115784265A (zh) | 一种氟磺酸锂的精制提纯方法 | |
CN106673996A (zh) | 一种提纯长链二羧酸的方法 | |
AU2002356773B2 (en) | Production of ammonium salts of aromatic carboxylic acids | |
CN115850278A (zh) | 二羟丙茶碱新晶型固体物质及其制备方法、注射液及其制备方法 | |
JP2002105097A (ja) | ステロール類の回収方法 | |
CN117735609A (zh) | 单相偏钨酸铵晶体的制备方法 | |
CN111699183A (zh) | 阿齐沙坦a型晶体的制造方法 | |
CN116081698A (zh) | 一种超临界流体辅助净化钛白废酸制备硫酸亚铁的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004553147 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006167290 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10532682 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A21537 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003811497 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057007883 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003811497 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057007883 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10532682 Country of ref document: US |